A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-08-28
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-10-03 (study day 27); relationship: N
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 348); relationship: not assessed
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-03-16 (study day 557); relationship: N
Data queries
No data queries.